Skip to main content
Karo Pharma AB logo

Karo Pharma AB — Investor Relations & Filings

Ticker · KARO ISIN · SE0007464888 LEI · 213800G54Z51LOPGTA79 ST Manufacturing
Open in API
Filings indexed 653 across all filing types
Latest filing 2019-12-02 Major Shareholding Noti…
Country SE Sweden
Listing ST KARO

About Karo Pharma AB

https://www.karohealthcare.com/

Karo Pharma AB, operating as Karo Healthcare, is a healthcare company that develops, markets, and sells a broad portfolio of everyday healthcare products. The company's offerings are designed to prevent illness and treat common health problems, empowering consumers to manage their daily well-being. The portfolio consists of various branded medicines and consumer healthcare products distributed through pharmacies and directly to healthcare providers. With products available in over 90 countries, the company focuses on becoming a leading force in its sector by employing a consumer-centric approach, strategic innovation, and omnichannel excellence.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2019
Major Shareholding Notification Classification · 99% confidence The document details a change in shareholding for 'Venture Holding S.a.r.l. SPF' in 'Karo Healthcare AB'. It explicitly states the 'Reason for major shareholding notification Buy' and provides 'Before the transaction' and 'After the transaction' figures for shares and voting rights, including percentages crossing a threshold (5%). This content directly corresponds to the definition of a Major Shareholding Notification, which is classified as 'MRQ' in the provided schema.
2019-12-02 English
Karo Pharma avyttrar Hydrokortison Trimb till Evolan Pharma
M&A Activity Classification · 99% confidence The document is a press release dated November 27, 2019, announcing that Karo Pharma is divesting the Hydrocortisone Trimb product and related assets to Evolan Pharma AB. This action was taken as a condition set by the Swedish Competition Authority (Konkurrensverket) to finalize a previous acquisition (Trimb Holding AB). The content focuses on a specific corporate transaction (divestiture/sale of assets) related to a prior merger/acquisition context. This fits best under the category for M&A Activity (TAR), as it is a direct consequence and component of completing a major corporate transaction (the acquisition of Trimb). It is not an Earnings Release (ER) as it focuses on a divestiture, not financial results highlights. It is not a general Regulatory Filing (RNS) because TAR is more specific. It is not a Capital/Financing Update (CAP) as it is an asset sale, not fundraising. Therefore, TAR is the most appropriate classification.
2019-11-27 Swedish
Karo Pharma divests Hydrokortison Trimb to Evolan Pharma
Regulatory Filings Classification · 99% confidence The document announces a specific corporate action: the divestment of a product (Hydrokortison Trimb) by Karo Pharma to Evolan Pharma, which was a condition for a prior acquisition. This transaction involves a change in assets and corporate structure related to business operations, but it is not a standard financial report (10-K, IR, ER), a management change (MANG), or a standard financing event (CAP). It is a specific corporate event announcement. Since there is no explicit category for 'Divestiture Announcement' or 'M&A Activity' that perfectly fits a partial asset sale resulting from a condition, I must evaluate the closest fit. M&A Activity (TAR) covers merger proposals or takeover bids. While this is a divestiture stemming from a prior acquisition, it is a significant transaction. However, given the nature of the announcement—a specific, non-financial, operational/strategic update—and the lack of a better fit among the provided codes, I will check if it fits 'Regulatory Filings' (RNS) as a general announcement. The text is a press release detailing a transaction approved by a competition authority. This type of material is often classified broadly. Since it is a specific corporate transaction announcement, and not a general regulatory filing fallback, I will re-evaluate TAR (M&A Activity). Divestitures are often grouped with M&A. Given the context of the prior acquisition (Trimb Holding AB), this divestiture is directly related to M&A activity. Therefore, TAR is the most appropriate classification for a significant transaction announcement like this.
2019-11-27 English
Förtydligande avseende ROR-gamma projektet
Legal Proceedings Report Classification · 99% confidence The document is a press release dated November 20, 2019, issued by Karo Pharma Aktiebolag. It serves as a clarification ('Förtydligande') regarding a previous announcement about the termination of a specific development project (ROR-gamma project) licensed from Pfizer. The text details the implications of this termination, specifically concerning milestone payments and the status of the overall agreement. This type of announcement, which provides specific, material updates on ongoing business operations, legal/licensing agreements, and financial outlook (by confirming milestone payments will not materialize), fits best under a general regulatory announcement category. Since it is not a full financial report (10-K, IR), an earnings release (ER), a management discussion (MDA), or a specific legal filing, it falls under the general regulatory announcement category, which is RNS (Regulatory Filings) as the fallback for miscellaneous regulatory announcements.
2019-11-20 Swedish
Further clarification regarding the ROR-gamma project
Regulatory Filings Classification · 95% confidence The document is a press release from Karo Pharma dated November 20, 2019, providing 'Further clarification regarding the ROR-gamma project' following a previous announcement about Pfizer terminating a development project. It details the implications of this termination on potential milestone payments and confirms the ongoing status of the broader Pfizer agreement. The text concludes by stating that 'This information is such information that Karo Pharma is obliged to make public pursuant to the EU Market Abuse Regulation.' This type of mandatory, specific corporate update that is not a full financial report (like 10-K or IR), a dividend notice, or a director's dealing, fits best under the general category for regulatory announcements that don't have a more specific code. While it is a clarification, it functions as a material event disclosure required by market regulations. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a mandatory, non-standard regulatory disclosure that isn't explicitly covered by other codes like DIRS, DIV, or ER. The document length (2683 chars) is short, suggesting it is an announcement rather than a full report.
2019-11-20 English
Interim / Quarterly Report 2019
Interim / Quarterly Report Classification · 100% confidence The document is titled 'DELÅRSRAPPORT JANUARI – SEPTEMBER 2019' (Interim Report January-September 2019). It contains comprehensive financial statements, including income statements, cash flow data, balance sheet summaries, and management commentary regarding the company's performance, acquisitions (Trimb), and organizational changes. It is a substantive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. 9M 2019
2019-11-15 Swedish

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.